Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch
Covered in this story
Call it yourself
No calls on $KRYS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Krystal Biotech Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.